Advancements in endometrial treatment – HUTCHMED & Innovent’s cancer combo NDA accepted with Priority Review April 2, 2024 AutoBot News 0 In an important announcement today (April 2), HUTCHMED and Innovent jointly revealed the acceptance of their New Drug Application (NDA) in China for the combination of Fruquintinib with Sintilimab.